Pharmaceutical Development and Technology · 2014 · 27 citations · 25 references
PharmacyPharmaceuticsPharmacologyDrug DeliveryNanoparticle Drug DeliveryOcular Drug DeliveryLipid-based NanoparticlesNanomaterials For Drug DeliveryNanomedicineNanoparticle DesignOcular NanocarriersAntioxidant Activity AssaysFree Radical ScavengingLeber Hereditary Optic NeuropathyLipid Nanoparticle DeliveryLipid NanoparticlesLipid-based Nanoparticle FormulationSolid Lipid EncapsulationSolvent Diffusion
Idebenone (IDE) is a lipophilic benzoquinone electron carrier synthetic analogue of coenzyme Q10, which behaves as an antioxidant and free radical scavenging molecule. Recently, the therapeutic application of IDE in Leber's hereditary optic neuropathy has been discussed. This work was aimed at evaluating the encapsulation of IDE in solid-lipid nanoparticles (SLN). In particular, we tested the possibility of adapting the quasi-emulsion solvent diffusion technique, already proposed to produce polymeric nanoparticles, to prepare positively charged SLN with different compositions. Such a charge, due to the addition of a cationic lipid, would facilitate the interaction with the negatively charged eye surface epithelium, with a consequent longer pre-corneal residence time of the colloidal systems. In a preliminary evaluation of the produced IDE-loaded SLN, the antioxidant activity of the drug was demonstrated using an oxygen radical absorbance capacity assay. Encapsulation of the drug in the nanocarrier systems seems able to protect IDE from degradation and prolong its antioxidant potential.
25
A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy
Thomas Klopstock, Patrick Yu‐Wai‐Man, Konstantinos Dimitriadis et al. · Brain · 2011 · 569 citations · Full text
Medicine, Neurology, Ophthalmology +17
Jonathan G. Merrell, S. McLaughlin, Lu Tie et al. · Clinical and Experimental Pharmacology and Physiology · 2009 · 427 citations
Leber’s Hereditary Optic Neuropathy
Alfredo A. Sadun, Chiara La Morgia, Valério Carelli · Current Treatment Options in Neurology · 2010 · 193 citations